Cargando…

A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders

Individuals with alcohol and/or drug use disorders often fail to receive care, or evidence-based care, yet the literature shows health economic benefits. Comparative effectiveness research is emerging that examines approved approaches in terms of real, total healthcare cost/utilization. Comprehensiv...

Descripción completa

Detalles Bibliográficos
Autor principal:	Gastfriend, David R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206699/ https://www.ncbi.nlm.nih.gov/pubmed/25236185 http://dx.doi.org/10.1111/nyas.12538

Ejemplares similares

Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses
por: Hadland, Scott E., et al.
Publicado: (2019)

Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events
por: Xu, Kevin Y., et al.
Publicado: (2021)

Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective
por: Gómez, Roberto E., et al.
Publicado: (2012)

Barriers to treatment of alcohol and tobacco use disorders in industrial workers
por: Sachdeva, Ankur, et al.
Publicado: (2022)

Looking at CER from the Pharmaceutical Industry Perspective
por: Dubois, Robert W.
Publicado: (2012)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Anti-Counterfeit Technologies: A Pharmaceutical Industry Perspective
por: Bansal, Dipika, et al.
Publicado: (2013)

Enzymatic Bioconjugation: A Perspective from the Pharmaceutical Industry
por: Debon, Aaron, et al.
Publicado: (2023)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

Ambulatory detoxification in alcohol use disorder and opioid use disorder
por: Moore, Troy A.
Publicado: (2020)

Evolving role of pharmaceutical physicians in the industry: Indian perspective
por: Patil, Anant, et al.
Publicado: (2012)

Perspective: Industry–patient relationships for the promotion of pharmaceutical agents
por: Bryarly, Meredith A., et al.
Publicado: (2023)

Opioid Treatment and Excessive Alcohol Consumption Are Associated With Esophagogastric Junction Disorders
por: Schindler, Valeria, et al.
Publicado: (2019)

Evaluation of Kratom Opioid Derivatives as Potential Treatment Option for Alcohol Use Disorder
por: Gutridge, Anna M., et al.
Publicado: (2021)

Use of Pharmacotherapies in the Treatment of Alcohol Use Disorders and Opioid Dependence in Primary Care
por: Lee, Jinhee, et al.
Publicado: (2015)

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
por: Reed, Megan K, et al.
Publicado: (2022)

Interacting with the Pharmaceutical Industry
por: Hayden, Stephen R.
Publicado: (2003)

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Alcohol use in opioid agonist treatment
por: Nolan, Seonaid, et al.
Publicado: (2016)

Preventing Opioid Use Disorders among Fishing Industry Workers
por: Walter, Angela Wangari, et al.
Publicado: (2018)

Chemical Engineering in the Pharmaceutical Industry, Active Pharmaceutical Ingredients
por: Ende, David
Publicado: (2019)

Association Between Opioid Use Disorder and Seizure Incidents Among Alcohol Use Disorder Patients
por: Furo, Hiroko, et al.
Publicado: (2023)

Dynamic Thinking Approach of Non-medical Use of Pharmaceutical Opioids
por: Zeinali, Farahnaz, et al.
Publicado: (2019)

Bi-directional Acceleration of Alcohol Use and Opioid Use Disorder
por: Huang, Wenfei, et al.
Publicado: (2019)

Practical Technology for Expanding and Improving Substance Use Disorder Treatment: Telehealth, Remote Monitoring, and Digital Health Interventions
por: Sweeney, Mary M., et al.
Publicado: (2022)

Pharmaceutical Formulation Facilities as Sources of Opioids and Other Pharmaceuticals to Wastewater Treatment Plant Effluents
por: Phillips, Patrick J., et al.
Publicado: (2010)

HPLC in the pharmaceutical industry /
Publicado: (1991)

Immunotoxicology in the pharmaceutical industry.
por: Norbury, K C
Publicado: (1982)

Pharmaceutical Industry in Syria
por: Kutaini, D
Publicado: (2010)

Identification and Treatment of Opioid Withdrawal and Opioid Use Disorder in the Emergency Department
por: Jennings, Lindsey, et al.
Publicado: (2020)

Determinants of Iran’s Bilateral Intra-industry Trade in Pharmaceutical Industry
por: Aghlmand, Siamak, et al.
Publicado: (2018)

Nutritional, pharmaceutical, and functional aspects of rambutan in industrial perspective: An updated review
por: Afzaal, Muhammad, et al.
Publicado: (2023)

Strategies to implement and sustain medication use for alcohol and opioid disorders
por: Ford, James H, et al.
Publicado: (2015)

Suicide Risk and Addiction: The Impact of Alcohol and Opioid Use Disorders
por: Rizk, Mina M., et al.
Publicado: (2021)

State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017
por: Luo, Feijun, et al.
Publicado: (2021)

Sustaining alcohol and opioid use disorder treatment in primary care: a mixed methods study
por: Hunter, Sarah B., et al.
Publicado: (2018)

Soft Targets: Nurses and the Pharmaceutical Industry
por: Jutel, Annemarie, et al.
Publicado: (2008)

Dark Nudges and Sludge in Big Alcohol: Behavioral Economics, Cognitive Biases, and Alcohol Industry Corporate Social Responsibility
por: PETTICREW, MARK, et al.
Publicado: (2020)

PLoS Medicine and the Pharmaceutical Industry
Publicado: (2006)

SAS programming in the pharmaceutical industry
por: Shostak, Jack
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_ansb5ke8f00c4e7t90n0f8qhgn